Form 4: Serina Therapeutics CSO Sells Shares After Option Exercise

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 535 common shares for a profit under a Rule 10b5-1 plan.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc. (SER), reported transactions on November 24, 2025.
• Exercised 535 stock options at an exercise price of $0.06 per share.
• Immediately sold 535 shares of common stock at a weighted average price of $3.935 per share.
• The sale price for the common stock ranged from $3.917 to $3.98 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan, indicating a pre-arranged sale.
• Following these transactions, Moreadith directly owns 0 common shares and 384,151 stock options.

Sentiment

Score: 6

Explanation: Slightly positive due to insider profit from option exercise, though the sale reduces direct equity stake. The 10b5-1 plan mitigates negative sentiment from insider selling.

Positives

• The Chief Scientific Officer realized a profit by exercising options at $0.06 and selling shares at a weighted average of $3.935.
• Transactions were executed under a Rule 10b5-1 plan, indicating pre-planned sales rather than reactive selling.

Negatives

• An insider reduced their direct common stock ownership by selling shares, even if pre-planned.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may note the Chief Scientific Officer's decision to monetize a portion of their equity compensation, which is a common practice for executives.

Key Dates

Recommendation

This Form 4 filing reports routine insider transactions (option exercise and sale) under a pre-arranged 10b5-1 plan. The number of shares involved is relatively small (535 shares), and while it represents a reduction in the Chief Scientific Officer's direct common stock holdings, it does not provide sufficient new information to warrant a change in investment recommendation. The profit realized by the insider is a positive, but the overall impact on the company's valuation or strategic direction is negligible. Investors should consider broader company fundamentals and market conditions rather than this specific insider transaction for investment decisions.

Keywords

Serina Therapeutics, SER, Form 4, Insider Trading, Stock Options, Randall Moreadith, Chief Scientific Officer, 10b5-1 Plan, Equity Sales